Sinovac Biotech Ltd.: Business Overview, Financials & Competitive Analysis
Sinovac Biotech Ltd. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Sinovac is a vaccine-focused biotech with established products but faces regulatory compliance risks and governance uncertainties that cap near-term upside potential. The company faces challenges indicated by its financial performance and may encounter hurdles in achieving sustainable growth. While the company remains under mandatory panel monitoring until May 20.
What is Sinovac Biotech Ltd.'s industry? Sinovac Biotech Ltd. (sinovac.com) operates in Vaccines. AskCyborg classifies Sinovac Biotech Ltd. under Vaccines in its company registry.
Sinovac Biotech Ltd. is a China-based global biopharmaceutical company focused on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The company's vaccine portfol...
Cyborg Score thesis
Sinovac is a vaccine-focused biotech with established products but faces regulatory compliance risks and governance uncertainties...
Read the full analyst-debate transcript →Get the Latest Sinovac Biotech Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSinovac Biotech Ltd. Overview
Pro stress-test →Sinovac Biotech Ltd. is a China-based global biopharmaceutical company focused on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The company's vaccine portfolio includes CoronaVac® for COVID-19 and Healive® for hepatitis, among other products.
Strategic Profile
Pro stress-test →Sinovac positions itself as a leading provider of biopharmaceutical products in China. The company has faced significant operational challenges, including compliance issues with Nasdaq filing requirements in 2025, triggering a delisting determination in November 2025. However, as of June 2026, the company has regained Nasdaq compliance after filing required annual and interim financial reports.
Competitive Landscape
Pro stress-test →Sinovac competes in the global vaccine market against major manufacturers including state-sponsored Chinese vaccine producers and international pharmaceutical firms. The company's primary market focus is China and emerging markets in Asia, Africa, and Latin America, where it competes on cost-effectiveness and government procurement relationships.
Industry Context
Sinovac Biotech Ltd. operates in Vaccines.
Key facts
Founded: 1999 · Headquarters: Beijing, China · Employees: 4,281 · Revenue: N/A · Market cap: N/A